A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

Polatuzumab vedotin (pola) is a CD79b‐targeted antibody‐drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open‐label, single‐arm study of pola 1.8 mg/kg, bendamustine 90 mg/m(2), rituximab 375 mg/m(2) (pola + BR) Q3W for up to six cycles in patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Terui, Yasuhito, Rai, Shinya, Izutsu, Koji, Yamaguchi, Motoko, Takizawa, Jun, Kuroda, Junya, Ishikawa, Takayuki, Kato, Koji, Suehiro, Youko, Fukuhara, Noriko, Ohmine, Ken, Goto, Hideki, Yamamoto, Kazuhito, Kanemura, Nobuhiro, Ueda, Yasunori, Ishizawa, Kenichi, Kumagai, Kyoya, Kawasaki, Atsuko, Saito, Tomohisa, Hashizume, Misato, Shibayama, Hirohiko
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8253277/
https://ncbi.nlm.nih.gov/pubmed/33942442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14937
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados